Press Room

DPI China 2024

Start
Thursday, March 21, 2024
End
Thursday, March 21, 2024
Location: Hangzhou, China
DPI China_2024_Hovione

Looking for a complete One-Site Solution for your inhalation and nasal therapies? Meet Hovione at the 11st DPI China Technology Conference! Delivering solutions every breath of the way.

We live and breathe innovation for the successful delivery of your inhalation and nasal therapies.

Hovione offers customized high-performance APIs, particle engineering and formulation along with a full range of highly specialized, patented and innovative devices, all in one site.

Don’t miss the chance to speak with our Inhalation Experts. 

On March 21, our team is at the 11th DPI China Technology Conference ready to share how this integration on a single site can support your project.

ORAL PRESENTATION – March 21

"End-to-end Respiratory Drug Delivery Platforms", with João Ventura, Product Management Director, Business Management Products.

The presentation will provide a perspective on the status and outlook of respiratory drug delivery and address the most relevant platforms for end-to-end dry powder inhalation (DPI) development, as DPIs are the dosage form of choice for achieving superior delivery efficiency to patients.

This presentation will focus on advanced particle engineering technologies for manufacturing inhalation active pharmaceutical ingredients (APIs), new formulation development platforms, aiming to address the pharmacokinetics requirements of the target drug and indication, and device developments for maximum drug delivery efficiency for lung delivery. An integrated, end-to-end development approach will be presented designed to maximize drug delivery efficiency and safety and address a diversified array of diseases.

 

Schedule a meeting today.

Learn more about our Inhalation and Nasal offering.

 

 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026